Bioasis is dedicated to delivering hope to patients suffering with neurological diseases and disorders. Our breakthrough science focuses on transporting medicines across the blood-brain barrier, providing a path to hundreds of previously untreatable diseases of the central nervous system.
1 in 6 People Worldwide
Neurological disease affects 1.25 billion people worldwide, and the incidence of these disorders is only increasing. Bioasis is determined to deliver effective treatments to patients suffering with these diseases.
Our Science
A Barrier to Better Health
The blood-brain barrier plays an essential role in protecting the brain from blood-borne disease. However, it also blocks otherwise effective medicine from reaching the brain. Most drugs created to treat central nervous system diseases and disorders fail because they aren't optimally designed to be delivered in sufficient quantities to the brain.
Blood-Brain Barrier
Transporting Treatment
The Bioasis xB3 platform provides researchers with a path for the delivery of treatments across the blood-brain barrier and into the brain. Our technology offers a solution to a problem that for decades has blocked development of effective treatment of neurological disorders.
Our Platform
Latest News
Bioasis Announces Key Strategic Appointment to its Senior Leadership Team with Addition of Caroline Hill, Ph.D., Leading Research & Development OperationsMar. 26, 2018
Bioasis Appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as Chair of the Board of DirectorsMar. 21, 2018
Dr. Rathjen is the Chief Executive Officer and Managing Director of Bionomics in Adelaide, Australia; Dr. Rathjen joined the Bioasis Board in September 2017
Bioasis to Present at the 20th Annual BIO CEO & Investor ConferenceFeb. 6, 2018